The role of biomarkers and imaging in Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 16, Issue 2, 2016, Pages 187-203

  Algarni, Musleh A ^a,b   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Al Thagher General Hospital   (Saudi Arabia)

Author keywords

biomarkers; diffusion tensor imaging; Parkinson's disease; positron emission tomography; SPECT; synuclein

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER; DOPAMINE; MOLECULAR MARKER; NEUROMELANIN; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN DEGLYCASE DJ-1; SIGNAL PEPTIDE; TAU PROTEIN;

ATYPICAL PARKINSONISM; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DOPAMINE METABOLISM; DOPAMINE REUPTAKE; DOPAMINE STORAGE; EARLY DIAGNOSIS; ENERGY METABOLISM; ESSENTIAL TREMOR; FUNCTIONAL NEUROIMAGING; HEALTH DISPARITY; HUMAN; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PARKINSONISM; POSTSYNAPTIC DOPAMINERGIC IMAGING; PRESYNAPTIC DOPAMINERGIC IMAGING; REVIEW; SYSTEMATIC REVIEW (TOPIC); BRAIN; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; DOPAMINERGIC NERVE CELL; GENETICS; INFLAMMATION; METABOLISM; MUTATION; NEUROIMAGING; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; FUNCTIONAL NEUROIMAGING; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAGNETIC RESONANCE IMAGING; MUTATION; NEUROIMAGING; ONCOGENE PROTEINS; OXIDATIVE STRESS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN DEGLYCASE DJ-1; SUBSTANTIA NIGRA; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84958121479     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2016.1135056     Document Type: Review

References (187)

1. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347-366.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20(4):415-455.
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-2301.
4. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology. 2014;83(5):406-412.
5. Goswami R, Ponde DE, Kung MP, et al. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33(6):685-694.
6. Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993;34(3):324-330.
7. Vingerhoets FJ, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41(1):58-64.
8. Sossi V, De L-F-F, Holden JE, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab. 2002;22(2):232-239.
9. Doudet DJ, Chan GL, Holden JE, et al. 6-[18F]Fluoro-LDOPA PET studies of the turnover of dopamine in MPTPinduced parkinsonism in monkeys. Synapse. 1998;29 (3):225-232.
10. Moore RY, Whone AL, McGowan S, et al. Monoamine neuron innervation of the normal human brain: an 18FDOPA PET study. Brain Res. 2003;982(2):137-145.
11. Pavese N, Simpson BS, Metta V, et al. [(1)(8)F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [(1)(8)F]FDOPA and [(1)(1)C]DASB PET study in Parkinson's disease. Neuroimage. 2012;59(2):1080-1084.
12. Whone AL, Moore RY, Piccini PP, et al. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol. 2003;53(2):206-213.
13. Hersch SM, Yi H, Heilman CJ, et al. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol. 1997;388(2):211-227.
14. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991;9(1):43-49.
15. Bezard E, Dovero S, Prunier C, et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci. 2001;21(17):6853-6861.
16. Niznik HB, Fogel EF, Fassos FF, et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem. 1991;56 (1):192-198.
17. Seibyl JP, Marek KL, Quinlan D, et al. Decreased singlephoton emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38(4):589-598.
18. Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.
19. Benamer HT, Patterson J, Wyper DJ, et al. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15(4):692-698.
20. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47(4):493-503.
21. Lin SC, Lin KJ, Hsiao IT, et al. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. J Nucl Med. 2014;55(1):73-79.
22. Vander Borght TM, Sima AA, Kilbourn MR, et al. [3H] methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68(3):955-962.
23. Vander BT, Kilbourn M, Desmond T, et al. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294(2-3):577-583.
24. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16(10):3507-3510.
25. Fuente-Fernandez R, Furtado S, Guttman M, et al. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse. 2003;49(1):20-28.
26. Fuente-Fernandez R, Sossi V, McCormick S, et al. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse. 2009;63(8):713-716.
27. Boileau I, Rusjan P, Houle S, et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci. 2008;28 (39):9850-9856.
28. Tong J, Wilson AA, Boileau I, et al. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse. 2008;62(11):873-876.
29. Antonini A, Schwarz J, Oertel WH, et al. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord. 1997;12 (1):33-38.
30. Kaasinen V, Ruottinen HM, Nagren K, et al. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41(1):65-70.
31. Sawle GV, Playford ED, Brooks DJ, et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications of the D2 receptor status. Brain. 1993;116(Pt 4):853-867.
32. Thobois S, Vingerhoets F, Fraix V, et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol. 2004;61(11):1705-1709.
33. Ma Y, Tang C, Spetsieris PG, et al. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007;27(3):597-605.
34. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26(3):912-921.
35. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain. 2007;130(Pt 7):1834-1846.
36. Lin TP, Carbon M, Tang C, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain. 2008;131(Pt 5):1373-1380.
37. Calne DB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature. 1985;317 (6034):246-248.
38. Piccini P, Burn DJ, Ceravolo R, et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45(5):577-582.
39. Adams JR, Van NH, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain. 2005;128(Pt 12):2777-2785.
40. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology. 2008;71(22):1790-1795.
41. Sossi V, Fuente-Fernandez R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord. 2010;25(16):2717-2723.
42. Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 2005;64(1):134-136.
43. Khan NL, Valente EM, Bentivoglio AR, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 2002;52(6):849-853.
44. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004;56(2):173-181.
45. Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology. 2014;83(19):1739-1746.
46. Postuma RB, Gagnon JF, Vendette M, et al. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296-1300.
47. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology. 2000;55(9):1410-1412.
48. Iranzo A, Valldeoriola F, Lomena F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011;10 (9):797-805.
49. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007;22(15):2210-2215.
50. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry. 2009;80 (7):744-748.
51. Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010;25(5):560-569.
52. Marshall VL, Patterson J, Hadley DM, et al. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun. 2006;27 (12):933-937.
53. Batla A, Erro R, Stamelou M, et al. Patients with scans without evidence of dopaminergic deficit: a long-term follow-up study. Mov Disord. 2014;29(14):1820-1825.
54. Marshall VL, Patterson J, Hadley DM, et al. Successful anti parkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Mov Disord. 2006;21(12):2247-2250.
55. Stoessl AJ, Halliday GM. DAT-SPECT diagnoses dopamine depletion, but not PD. Mov Disord. 2014;29(14):1705-1706.
56. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991;54(5):388-396.
57. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease Pathophysiologic and Clinical Implications. N Engl J Med. 1988;318(14):876-880.
58. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997;120(Pt 12):2187-2195.
59. Eckert T, Van LK, Tang C, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging. 2007;34 (4):496-501.
60. Tang CC, Poston KL, Dhawan V, et al. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci. 2010;30 (3):1049-1056.
61. Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol. 1993;33(5):518-527.
62. Antonini A, Kazumata K, Feigin A, et al. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov Disord. 1998;13(2):268-274.
63. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9(2):149-158.
64. Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15 (3):503-510.
65. Benaderette S, Zanotti FP, Apartis E, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord. 2006;21 (3):310-317.
66. Felicio AC, Godeiro-Junior C, Moriyama TS, et al. Degenerative parkinsonism in patients with psychogenic parkinsonism: A dopamine transporter imaging study. Clin Neurol Neurosurg. 2010;112(4):282-285.
67. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155(1):60-67.
68. Raffel DM, Koeppe RA, Little R, et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med. 2006;47(11):1769-1777.
69. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46(1):231-237.
70. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26(9):1198-1212.
71. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain. 2009;132(Pt 11):2970-2979.
72. Bruck A, Aalto S, Rauhala E, et al. A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord. 2009;24(7):1009-1015.
73. Tatton WG, Chalmers-Redman R, Brown D, et al. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol. 2003;53(Suppl 3):S61-S70.
74. Muchowski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron. 2002;35(1):9-12.
75. Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol. 1998;44(3 Suppl 1):S89-S98.
76. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain. 2013;136(Pt 8):2419-2431.
77. Nurmi E, Bergman J, Eskola O, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse. 2003;48(3):109-115.
78. Schulzer M, Lee CS, Mak EK, et al. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain. 1994;117(Pt 3):509-516.
79. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378-382.
80. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64(3):314-319.
81. Fuente-Fernandez R, Schulzer M, Kuramoto L, et al. Agespecific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol. 2011;69(5):803-810.
82. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain. 2011;134(Pt 11):3290-3298.
83. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain. 2006;129(Pt 10):2667-2678.
84. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931-1938.
85. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93-101.
86. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508.
87. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344(10):710-719.
88. Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol. 2001;50(2):181-187.
89. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54(3):403-414.
90. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59(3):459-466.
91. Piccini P, Lindvall O, Bjorklund A, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000;48(5):689-695.
92. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007;369(9579):2097-2105.
93. Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and metaanalysis. Neurology. 2013;80(9):857-864.
94. Vaillancourt DE, Spraker MB, Prodoehl J, et al. Highresolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009;72(16):1378-1384.
95. Zhan W, Kang GA, Glass GA, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. Mov Disord. 2012;27(1):90-97.
96. Ofori E, Pasternak O, Planetta PJ, et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. Brain. 2015 Aug;138(Pt 8):2322-2331.
97. Wang JJ, Lin WY, Lu CS, et al. Parkinson disease: diagnostic utility of diffusion kurtosis imaging. Radiology. 2011;261(1):210-217.
98. Kamagata K, Tomiyama H, Motoi Y, et al. Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: comparison with conventional diffusion tensor imaging. Magn Reson Imaging. 2013;31(9):1501-1506.
99. Kamagata K, Tomiyama H, Hatano T, et al. A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. Neuroradiology. 2014;56(3):251-258.
100. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain. 2006;129(Pt 10):2679-2687.
101. Ogisu K, Kudo K, Sasaki M, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology. 2013;55(6):719-724.
102. Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord. 2014;20(7):755-760.
103. Reimao S, Pita LP, Neutel D, et al. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. Eur J Neurol. 2015;22 (3):540-546.
104. Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O, et al. Automated neuromelanin imaging as a diagnostic biomarker for parkinson's disease. Mov Disord. 2015 Jun;30(7):945-952.
105. Reimao S, Pita LP, Neutel D, et al. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. Mov Disord. 2015 Jun;30 (7):953-959.
106. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology. 2008;70(16 Pt 2):1411-1417.
107. Lehericy S, Bardinet E, Poupon C, et al. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Mov Disord. 2014;29 (13):1574-1581.
108. Schwarz ST, Afzal M, Morgan PS, et al. The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014;9(4): e93814.
109. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain. 2010;133(11):3423-3433.
110. Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 1995;45(1):182-184.
111. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology. 1999;53(5):1026-1031.
112. Stockner H, Sojer M, Ks K, et al. Midbrain sonography in patients with essential tremor. Mov Disord. 2007;22 (3):414-417.
113. Berg D, Merz B, Reiners K, et al. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord. 2005;20(3):383-385.
114. Pyatigorskaya N, Sharman M, Corvol JC, et al. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2∗ relaxometry. Mov Disord. 2015 Jul;30(8):1077-1084.
115. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol. 1999;45 (1):65-74.
116. Ghaemi M, Hilker R, Rudolf J, et al. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multitracer PET imaging. J Neurol Neurosurg Psychiatry. 2002;73(5):517-523.
117. Krabbe K, Karlsborg M, Hansen A, et al. Increased intracranial volume in Parkinson's disease. J Neurol Sci. 2005;239(1):45-52.
118. Pitcher TL, Melzer TR, Macaskill MR, et al. Reduced striatal volumes in Parkinson's disease: a magnetic resonance imaging study. Transl Neurodegener. 2012;1(1):17.
119. Nagano-Saito A, Washimi Y, Arahata Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology. 2005;64(2):224-229.
120. Burton EJ, McKeith IG, Burn DJ, et al. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord. 2005;20 (12):1571-1576.
121. Guevara CA, Blain CR, Stahl D, et al. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol. 2010;17(9):1193-1202.
122. Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol. 1995;37(2):204-210.
123. Tedeschi G, Litvan I, Bonavita S, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain. 1997;120(Pt 9):1541-1552.
124. Federico F, Simone IL, Lucivero V, et al. Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes. Ital J Neurol Sci. 1999;20 (4):223-229.
125. Ellis CM, Lemmens G, Williams SC, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology. 1997;49(2):438-444.
126. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol. 2000;7(6):661-665.
127. Holshouser BA, Komu M, Moller HE, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med. 1995;33(5):589-594.
128. Seraji-Bozorgzad N, Bao F, George E, et al. Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study. Mov Disord. 2015;30(10):1400-1404.
129. Choe BY, Park JW, Lee KS, et al. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol. 1998;33(8):450-455.
130. Oz G, Terpstra M, Tkac I, et al. Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med. 2006;55(2):296-301.
131. Emir UE, Tuite PJ, Oz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One. 2012;7(1):e30918.
132. O'Neill J, Schuff N, Marks WJ Jr., et al. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord. 2002;17(5):917-927.
133. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain. 2009;132(Pt 12):3285-3297.
134. Groger A, Chadzynski G, Godau J, et al. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol. 2011;21(9):1962-1969.
135. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
136. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357-367.
137. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79 (6):1094-1108.
138. Shah M, Seibyl J, Cartier A, et al. Molecular imaging insights into neurodegeneration: focus on alpha-synuclein radiotracers. J Nucl Med. 2014;55(9):1397-1400.
139. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57(2):168-175.
140. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21(2):404-412.
141. Koshimori Y, Ko JH, Mizrahi R, et al. Imaging striatal microglial activation in patients with parkinson's disease. PLoS One. 2015;10(9):e0138721.
142. Sako W, Murakami N, Izumi Y, et al. Reduced alphasynuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord. 2014;29 (13):1599-1605.
143. Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014;184(4):966-975.
144. van Dijk KD, Bidinosti M, Weiss A, et al. Reduced alphasynuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur J Neurol. 2014;21(3):388-394.
145. Hall S, Surova Y, Ohrfelt A, et al. CSF biomarkers and clinical progression of Parkinson disease. Neurology. 2015;84(1):57-63.
146. Park MJ, Cheon SM, Bae HR, et al. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol. 2011;7(4):215-222.
147. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75 (20):1766-1772.
148. Aasly JO, Johansen KK, Bronstad G, et al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front Aging Neurosci. 2014;6:248.
149. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133(Pt 3):713-726.
150. Shi M, Furay AR, Sossi V, et al. DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging. 2012;33(4):836-837.
151. Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010;25(15):2682-2685.
152. Alves G, Lange J, Blennow K, et al. CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82(20):1784-1790.
153. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-580.
154. Aasly JO, Shi M, Sossi V, et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology. 2012;78(1):55-61.
155. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-529.
156. Parnetti L, Chiasserini D, Bellomo G, et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord. 2011;26(8):1428-1435.
157. Parnetti L, Chiasserini D, Persichetti E, et al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Mov Disord. 2014;29(8):1019-1027.
158. Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015 Nov;86(11):1240-1247.
159. Shen C, Guo Y, Luo W, et al. Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci. 2013;40(1):73-79.
160. Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166 (5):561-567.
161. Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723.
162. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-1468.
163. Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord. 2008;23(12):1653-1657.
164. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;131(Pt 2):389-396.
165. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology. 2005;64(6):1081-1083.
166. Ihara Y, Chuda M, Kuroda S, et al. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. J Neurol Sci. 1999;170(2):90-95.
167. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, et al. Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol. 2007;58(2):78-83.
168. Isobe C, Murata T, Sato C, et al. Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. J Clin Neurosci. 2007;14(4):340-343.
169. Sohmiya M, Tanaka M, Tak NW, et al. Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci. 2004;223 (2):161-166.
170. Ilic TV, Jovanovic M, Jovicic A, et al. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol. 1999;14(3):141-147.
171. Chen H, O'Reilly EJ, Schwarzschild MA, et al. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008;167(1):90-95.
172. Rentzos M, Nikolaou C, Andreadou E, et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand. 2009;119(5):332-337.
173. Sutherland GT, Matigian NA, Chalk AM, et al. A crossstudy transcriptional analysis of Parkinson's disease. PLoS One. 2009;4(3):e4955.
174. Grunblatt E, Zehetmayer S, Jacob CP, et al. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm. 2010;117(12):1387-1393.
175. Licker V, Kovari E, Hochstrasser DF, et al. Proteomics in human Parkinson's disease research. J Proteomics. 2009;73(1):10-29.
176. Jin J, Hulette C, Wang Y, et al. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics. 2006;5(7):1193-1204.
177. Pan S, Rush J, Peskind ER, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008;7(2):720-730.
178. Li YH, Wang J, Zheng XL, et al. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with magnetic beads for detecting serum protein biomarkers in parkinson's disease. Eur Neurol. 2011;65(2):105-111.
179. Alberio T, Pippione AC, Zibetti M, et al. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease. Sci Rep. 2012;2:953.
180. Zhao X, Xiao WZ, Pu XP, et al. Proteome analysis of the sera from Chinese Parkinson's disease patients. Neurosci Lett. 2010;479(2):175-179.
181. Goodacre R, Vaidyanathan S, Dunn WB, et al. Metabolomics by numbers: acquiring and understanding globalmetabolite data. Trends Biotechnol. 2004;22(5):245-252.
182. Ahmed SS, Santosh W, Kumar S, et al. Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci. 2009;16:63.
183. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One. 2009;4(10):e7551.
184. Tan YY, Wu L, Zhao ZB, et al. Methylation of alphasynuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients. Parkinsonism Relat Disord. 2014;20(3):308-313.
185. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol. 2011;152(3):96-101.
186. Serafin A, Foco L, Zanigni S, et al. Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD. Neurology. 2015;84(7):645-653.
187. Salvatore C, Cerasa A, Castiglioni I, et al. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and Progressive Supranuclear Palsy. J Neurosci Methods. 2014;222:230-237.